Amsterdam, December 11, 2012 - Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today publication of Reproductive Health Matters' 2012 supplement issue "Pregnancy decisions of women living with HIV".
The supplement issue focuses on finding ways to work across disciplines with the goal of ensuring that women living with HIV are at the centre of decision-making about their sexual and reproductive health and rights. With the advent of antiretroviral therapy and with continued channeling of resources into HIV services, greater numbers of HIV-positive women are living longer, healthier lives. As a result, they are contending with a range of issues affecting their sexual and reproductive health and rights.
Papers published in the issue highlight a need for stronger evidence-based research; drawing from biomedical, economic, political, legal and social sciences alike. It also recognizes the importance of moving beyond the disciplinary silos to bring perspectives together in order to provide more comprehensive information relevant to the lives of these women. Together these papers are intended to inform and help drive policy, program building, research and advocacy efforts to promote and protect the sexual and reproductive health and rights of women living with HIV.
All papers included in the supplement issue are freely available at: http://www.
Notes to editors
The supplement issue "Pregnancy decisions of women living with HIV" of Reproductive Health Matters, Volume 20, Issue 39, Supplement pp. 1-140 (December 2012) published by Elsevier, is now available on ScienceDirect.
About Reproductive Health Matters (RHM)
Reproductive Health Matters is published twice a year, in May and November in English, with editions in translation in Arabic, Chinese, French, Hindi, Portuguese, Russian and Spanish. RHM covers laws, policies, research and services that meet women's reproductive health needs. Each issue focuses on a main theme and includes feature papers, topical papers on other subjects and a round-up of information from published literature.
Elsevier is a world-leading publisher of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell, and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include SciVerse ScienceDirect, SciVerse Scopus, Reaxys, MD Consult and Nursing Consult, which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review, which help research and health care institutions deliver better outcomes more cost-effectively.
A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC, a world-leading publisher and information provider, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).
+44 207 267 6567